Related Experiment Video

Updated: May 7, 2026

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

Calcitonin gene-related peptide receptor antagonists: beyond migraine pain--a possible analgesic strategy for

C M Bullock1, S Kelly

  • 1Arthritis Research UK Pain Centre, School of Biosciences, University of Nottingham, Sutton Bonington Campus, Leicestershire, LE12 5RD, UK, stxcb1@nottingham.ac.uk.

Current Pain and Headache Reports
|September 27, 2013
PubMed

Insights

Calcitonin gene-related peptide (CGRP) is linked to osteoarthritis pain. Investigating CGRP receptor antagonists, effective for migraines, may offer new osteoarthritis pain relief strategies.

Area of Science:

  • Neuroscience
  • Rheumatology
  • Pharmacology

Background:

  • Osteoarthritis (OA) pain management is challenging due to limited efficacy and side effects of current analgesics.
  • Understanding OA pain mechanisms is crucial for developing better pain treatments.
  • Clinical and preclinical data suggest a link between joint calcitonin gene-related peptide (CGRP) levels and OA pain.

Purpose of the Study:

  • To review the role of CGRP in pain mechanisms.
  • To examine emerging evidence for CGRP's involvement in OA pain.
  • To assess the potential of CGRP receptor antagonists for OA pain.

Main Methods:

  • Review of clinical and preclinical studies on CGRP and pain.
  • Analysis of existing data on CGRP levels in OA joints.
  • Evaluation of CGRP receptor antagonist efficacy in other pain conditions.

Main Results:

  • CGRP is a key sensory neuropeptide involved in pain signaling.
  • Evidence suggests an association between joint CGRP and OA pain.
  • CGRP receptor antagonists show efficacy in migraine pain.

Conclusions:

  • The role of CGRP in OA pain warrants further investigation.
  • CGRP receptor antagonists developed for migraine pain are promising candidates for OA pain management.
  • Targeting CGRP may represent a novel therapeutic strategy for osteoarthritis pain.

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Nociception01:44

Nociception

Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...